Preferred Label : EGFR Mutant-selective Inhibitor BPI-361175;
NCIt synonyms : EGFR TKI BPI-361175; EGFR Inhibitor BPI-361175;
NCIt definition : An orally bioavailable, mutant-selective, fourth-generation epidermal growth factor
receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration,
EGFR mutant-selective inhibitor BPI-361175 targets, binds to and inhibits the activity
of EGFR with C797S and other related mutations, thereby preventing EGFR-mediated signaling.
This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor
cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a
key role in tumor cell proliferation and tumor vascularization. BPI-361175 inhibits
mutated forms of EGFR with C797S and other related mutations that are resistant to
third-generation EGFR inhibitors.;
Molecule name : BPI-361175; BPI 361175;
NCI Metathesaurus CUI : CL1792215;
Origin ID : C187290;
UMLS CUI : C5706391;
Semantic type(s)
- concept_is_in_subset
- has_target
